Fulgent Genetics expands skeletal dysplasia panel by 188 genes and vascular panel by 29

Fulgent Genetics expands skeletal dysplasia panel by 188 genes and vascular panel by 29
Fulgent Genetics expands gene panels

Fulgent Genetics reported a significant expansion of its genetic testing panels, adding 188 genes to its skeletal dysplasia panel and 29 to its vascular malformation panel last month.

The broader coverage aims to improve diagnostic options for patients with rare diseases. Fulgent Genetics also invited feedback from clinicians on how expanded panels may have changed the diagnostic path for their patients, encouraging engagement on the impact of such advances.

Fulgent Genetics has recently increased its genomics outreach through research publications, podcasts, and conference presentations, as detailed in company disclosures. The firm has also updated its protocols for genetic variant reclassification and issued recommendations on the use of segregation testing, according to previous company guidance. These activities reflect ongoing efforts to support clinicians and enhance genetic testing practices.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.